Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Prostate Clear all

Conditions: Prostate Cancer
Interventions: PS 341, Docetaxel; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Fatigue
Interventions: Exercise; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 21 Years and older · Male only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Prostate Cancer
Interventions: trastuzumab, docetaxel; Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 4
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 1 more

Conditions: Prostate Cancer
Interventions: rituximab; Drug
Lead sponsor: Christopher Kane; Other
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Prostate Cancer
Interventions: Ultrasound and MRI, Ultrasound; Device
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent
Interventions: 68Ga-PSMA-11, Positron Emission Tomography/Computed Tomography; Drug · Procedure
Lead sponsor: Dana Mathews; Other
Eligibility: 18 Years and older · Male only
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prostate Cancer
Interventions: selenium, placebo; Dietary Supplement · Other
Lead sponsor: University of Arizona; Other
Eligibility: Up to 85 Years · Male only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Metastatic Prostate Cancer, Cancer of the Prostate, Prostate Cancer
Interventions: Anti-OX40, Radiation, Cyclophosphamide; Drug · Radiation
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Prostate Cancer
Interventions: Questionaires, fMRI scan (optional); Behavioral · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 65 Years and older · Male only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 2
States / cities: Duarte, California • New York, New York

Conditions: Prostate Cancer
Interventions: Gabapentin, Venlafaxine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Breast Cancer, Lung Cancer (Diagnosis), Prostate Cancer
Interventions: referral for definitive diagnosis based on their cancer screening results, Engagement; Behavioral
Lead sponsor: AdventHealth; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer, Cancer of Prostate, Prostatic Cancer, Cancer of the Prostate
Interventions: YM155; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 7
States / cities: Tuscon, Arizona • Los Angeles, California • Coeur d'Alene, Idaho + 4 more

Conditions: Prostate Cancer
Interventions: custom device to demonstrate a significant difference in electrical impedance signatures; Device
Lead sponsor: Ryan J. Halter; Other
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Prostate Cancer
Interventions: Leuvectin; Biological
Lead sponsor: Vical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 2
States / cities: Los Angeles, California • Cleveland, Ohio

Conditions: Adenocarcinoma of the Prostate, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions: anti-PSMA monoclonal antibody MDX1201-A488, robot-assisted laparoscopic surgery, diffuse optical imaging, pharmacological study, Laboratory Biomarker, Questionnaire; Biological · Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 36 Years to 74 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Duarte, California

Conditions: Melanoma
Interventions: Blood Draw; Other
Lead sponsor: Wolfram Samlowski; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Prostate Cancer
Interventions: Ad5-yCD/mutTKSR39rep-hIL12; Biological
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions: Calcitriol, Ketoconazole, Laboratory Biomarker Analysis, Pharmacological Study, Therapeutic Hydrocortisone; Dietary Supplement · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Prostate Cancer (Adenocarcinoma), Metastatic Prostate Cancer
Interventions: Abiraterone acetate, Dexamethasone, Metronidazole; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
Interventions: CT (Computed Tomography), Gallium Ga 68-DOTATATE, Positron Emission Tomography; Procedure · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Prostate Cancer
Interventions: BPX-601; Genetic
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Atlanta, Georgia • Hackensack, New Jersey • Portland, Oregon

Conditions: Prostate Cancer
Interventions: lycopene supplement, fish oil supplement, Placebo; Dietary Supplement · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: Male only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Solid Tumors, Cancer
Interventions: Cabozantinib, Placebo; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 34
States / cities: Scottsdale, Arizona • Sacramento, California • San Francisco, California + 30 more

Search by objective public record fields.

Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

Exercise for Prostate Cancer Patients

Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy

Prostate Cancer Detection Screening MRI Protocol

Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer

Selenium in Treating Patients With Prostate Cancer

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older

Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer

Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots

A Study of Telemedicine Shared Medical Appointments (SMAs) Versus Individual Telemedicine Visits for People With Prostate Cancer

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

Microendoscopic EI Sensing for Real-time Intraoperative Surgical Margin Assessment

Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer

Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer

Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers

Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer

Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer

A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies